CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
NPX-101 is a non-invasive device designed to treat moderate to severe depression, particularly for patients resistant to current medications. Utilizing Transcranial Magnetic Stimulation, it offers a more effective and comfortable therapy option.
Over 450 million individuals face depression, with over 800,000 suicide deaths per year, delivering a death rate of one person every 40 seconds.
These figures are set to increase as estimates put 1 out of 4 individuals in the future to face similar mental disorders at some stage of life.NPX-101 is the first product line for treating moderate to severe depression, especially the 30% of patients who are currently drug-resistant.
It is a patented non-invasive bioelectronic device that delivers Tran…
NEUROPREX EUROPE INC LTD
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, OXFORDSHIRE
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
